Northern Biologics Inc., of Toronto, is collaborating with Applied Biomath LLC, of Lincoln, Mass., in which the latter's hybrid modeling approach using both traditional pharmacokinetic/pharmacodynamic (PK/PD) models as well as semimechanistic PK/PD models will support an IND for Northern's biotherapeutic candidate in oncology. Applied Biomath will develop models for mouse, cynomolgus monkey and humans with cancer, the latter of which will be used to aid the prediction of first-in-human doses.